Too Old for MHT? The Two Questions Hidden Inside One

Why hormone therapy after 60 is not one conversation — and what the current evidence actually says.

You are sitting across from your GP. You bring up the symptoms that have been shaping your days — the broken sleep, the joint pain that was not there a year ago, the brain fog you keep apologising for. You ask about hormone therapy.

You are told you are too old.

Maybe you are approaching 60 and your GP says it is time to stop after ten years. Maybe you are past 60 and have been told you missed the window entirely.

I am a Former Registered Nurse and a Menopause Mentor. I work with women in exactly this position — and what I want you to know is that the conversation about hormone therapy after 60 has changed substantially in recent years. Most women have not been told what has changed. (IMS 2024; NAMS 2022.)

There is no single answer — because there is no single question

"Am I too old for MHT?" is not one conversation. It is two. Systemic MHT and vaginal MHT are different treatments. They have different absorption profiles. They have different criteria. The answer to "is this safe for me?" is not the same for both. (AMS 2024; NICE NG23 2024; IMS 2024.)

Once you separate them, the rest becomes much clearer.

Question 1: Vaginal oestrogen

Vaginal oestrogen treats genitourinary syndrome of menopause — vaginal and vulval dryness, painful sex, urinary urgency, and recurrent UTIs that affect around half of postmenopausal women. (NAMS 2020.)

It works locally on vaginal and urinary tissue. Systemic absorption is minimal.

There is no age cutoff for vaginal oestrogen. It is considered safe to start or continue at any age — into your 70s, 80s, and beyond. This position is supported by AMS, NICE, and the International Menopause Society. (AMS 2024; NICE NG23 2024; IMS 2024.)

In Australia, the available forms are Ovestin cream (with applicator), Ovestin pessary (inserted by finger), and Vagifem pessary (with applicator). If one form does not suit you, another might.

This is the conversation many women never have — and one that can change quality of life significantly.

Question 2: Systemic MHT after 60

Whether you are still a candidate for systemic MHT depends on what your cardiovascular system and overall health look like today. (IMS 2024.)

What matters here is what your blood pressure, lipid profile, and metabolic markers show, whether you have established cardiovascular disease, stroke history, or specific cancers, and what form of MHT is being considered. Transdermal patches and gels have a different safety profile to oral tablets, particularly for venous thromboembolism risk. (Vinogradova et al 2019.)

If those markers and your overall health are favourable, the decision to continue or to start is reasonable to revisit with a GP who has menopause training. The recommendation to stop based on age alone is no longer evidence-based. The 5- and 10-year time limits women were once told are no longer supported by current guidance, and approaching 60 is not, on its own, a reason to stop. (IMS 2024; NAMS 2022.)

What to do before your next appointment

Track your symptoms for two to three months. Sleep, mood, joints, urinary symptoms, sexual function, hot flushes, brain fog. Make the list specific.

Take it with you. Ask the two questions separately — they have different answers.

You are entitled to be taken seriously. You are entitled to a second opinion if you are dismissed.

This information is educational only and does not constitute personal medical advice. Always consult a qualified health professional about your individual circumstances.

© 2026 Menopause Hub | Anna Pattison | menopausehub.com.au

Anna Pattison — Former Registered Nurse, Clinical Myotherapist, Menopause Mentor. Postgraduate Certificate in Menopause Medicine (University of South Wales).

References

Australasian Menopause Society (AMS). Information sheets on hormone replacement therapy and vaginal oestrogen. menopause.org.au (accessed 2026).

NICE. Menopause: diagnosis and management. Guideline NG23, updated 2024. nice.org.uk

International Menopause Society (IMS). Recommendations on women's midlife health and menopause hormone therapy. Climacteric (2024 update).

North American Menopause Society (NAMS). The 2022 Hormone Therapy Position Statement. Menopause 2022;29(7):767-794.

NAMS. The 2020 Genitourinary Syndrome of Menopause Position Statement. Menopause 2020;27(9):976-992.

Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The Women's Health Initiative randomized trials. JAMA 2017;318(10):927-938.

Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019;364:k4810.

Baik SH, et al. Long-term safety of vaginal oestrogen in postmenopausal women: large-scale electronic health records analysis. 2024.